Literature DB >> 23624362

Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women.

Sandra Blitz1, Joanna Baxter, Janet Raboud, Sharon Walmsley, Anita Rachlis, Fiona Smaill, Alex Ferenczy, François Coutlée, Catherine Hankins, Deborah Money.   

Abstract

BACKGROUND: The Canadian Women's HIV Study (CWHS) enrolled human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women in a longitudinal cohort. This analysis considered the effects of HIV and highly active antiretroviral therapy (HAART) on HPV persistence and cervical squamous intraepithelial lesions (SILs).
METHODS: Longitudinal cytopathologic and HPV DNA results were analyzed using multistate models. States of cervical SIL were defined as absent, present, and treatment; HPV states were defined as negative or positive. Demographic variables and markers of sexual activity were considered predictors. Results were calculated on the basis of transition probabilities and reported as hazard ratios (HRs).
RESULTS: The CWHS followed 750 HIV-positive and 323 HIV-negative women during 1993-2002. A total of 467 and 456 women were included in the longitudinal cervical cytopathologic and HPV DNA analyses, respectively. HIV-positive women had increased prevalence (46.6% vs 28.7%; P < .0001), increased acquisition (HR, 2.3; P = .03), and decreased clearance (HR, 0.4; P < .001) of oncogenic HPV as compared to HIV-negative women. Oncogenic HPV infection predicted progression of cervical dysplasia from normal to abnormal SIL (HR, 2.8; P = .002). Among HIV-positive participants, HAART increased the likelihood of regression (from present to absent) of cervical SIL (HR, 3.3; P = .02) and increased the clearance of oncogenic HPV types other than HPV-16 or HPV-18 (HR, 2.2; P = .01).
CONCLUSIONS: This analysis demonstrated beneficial effects of HAART on cervical SIL in HIV-positive women.

Entities:  

Keywords:  HAART; HIV; HPV; cervical cancer; cervical dysplasia; cervical squamous intraepithelial lesion; women

Mesh:

Year:  2013        PMID: 23624362     DOI: 10.1093/infdis/jit181

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

Review 1.  Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era.

Authors:  Cristina Brickman; Joel M Palefsky
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

2.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

Review 3.  The interaction between human papillomavirus and other viruses.

Authors:  J T Guidry; R S Scott
Journal:  Virus Res       Date:  2016-11-05       Impact factor: 3.303

4.  Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.

Authors:  Dmitri Madera; Lynn Vitale-Cross; Daniel Martin; Abraham Schneider; Alfredo A Molinolo; Nitin Gangane; Thomas E Carey; Jonathan B McHugh; Christine M Komarck; Heather M Walline; William N William; Raja R Seethala; Robert L Ferris; J Silvio Gutkind
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-13

5.  Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.

Authors:  Daniel C Beachler; Elizabeth A Sugar; Joseph B Margolick; Kathleen M Weber; Howard D Strickler; Dorothy J Wiley; Ross D Cranston; Robert D Burk; Howard Minkoff; Susheel Reddy; Weihong Xiao; Yingshi Guo; Maura L Gillison; Gypsyamber D'Souza
Journal:  Am J Epidemiol       Date:  2014-12-04       Impact factor: 4.897

6.  HIV Infection and Survival Among Women With Cervical Cancer.

Authors:  Scott Dryden-Peterson; Memory Bvochora-Nsingo; Gita Suneja; Jason A Efstathiou; Surbhi Grover; Sebathu Chiyapo; Doreen Ramogola-Masire; Malebogo Kebabonye-Pusoentsi; Rebecca Clayman; Abigail C Mapes; Neo Tapela; Aida Asmelash; Heluf Medhin; Akila N Viswanathan; Anthony H Russell; Lilie L Lin; Mukendi K A Kayembe; Mompati Mmalane; Thomas C Randall; Bruce Chabner; Shahin Lockman
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

7.  Outcomes Up to 12 Months After Treatment With Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia Among HIV-Infected Women.

Authors:  Megan J Huchko; Hannah Leslie; May Maloba; Jennifer Zakaras; Elizabeth Bukusi; Craig R Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

8.  Colposcopic Study of Lower Genital Tract Infections in HIV-Positive Women on Antiretroviral Therapy.

Authors:  Poorva Badkur; Kavita N Singh; Vineeta Ghanghoriya
Journal:  J Obstet Gynaecol India       Date:  2016-03-11

9.  The relation of plasmacytoid dendritic cells (pDCs) and regulatory T-cells (Tregs) with HPV persistence in HIV-infected and HIV-uninfected women.

Authors:  Howard D Strickler; Jeffrey Martinson; Seema Desai; Xianhong Xie; Robert D Burk; Kathryn Anastos; L Stewart Massad; Howard Minkoff; Xiaonan Xue; Gypsyamber D'Souza; Alexandra M Levine; Christine Colie; D Heather Watts; Joel M Palefsky; Alan Landay
Journal:  Viral Immunol       Date:  2014-02       Impact factor: 2.257

Review 10.  Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk.

Authors:  Alvaro H Borges; Robert Dubrow; Michael J Silverberg
Journal:  Curr Opin HIV AIDS       Date:  2014-01       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.